346 related articles for article (PubMed ID: 28094846)
1. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
[TBL] [Abstract][Full Text] [Related]
2. Cardiac safety assessment with motion field imaging analysis of human iPS cell-derived cardiomyocytes is improved by an integrated evaluation with cardiac ion channel profiling.
Isobe T; Honda M; Komatsu R; Tabo M
J Toxicol Sci; 2019; 44(12):859-870. PubMed ID: 31813905
[TBL] [Abstract][Full Text] [Related]
3. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
[TBL] [Abstract][Full Text] [Related]
4. Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?
Sala L; Bellin M; Mummery CL
Br J Pharmacol; 2017 Nov; 174(21):3749-3765. PubMed ID: 27641943
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
Takasuna K; Kazusa K; Hayakawa T
Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
[TBL] [Abstract][Full Text] [Related]
6. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
[TBL] [Abstract][Full Text] [Related]
7. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
[TBL] [Abstract][Full Text] [Related]
8. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
9. Video-based assessment of drug-induced effects on contractile motion properties using human induced pluripotent stem cell-derived cardiomyocytes.
Okai Y; Matsune K; Yamanaka K; Matsui T; Pfeiffer Kaushik E; Harada K; Kohara H; Miyawaki A; Ozaki H; Wagoner M; Shinozawa T
J Pharmacol Toxicol Methods; 2020 Sep; 105():106893. PubMed ID: 32619502
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Troponins are Among Targets of Doxorubicin-Induced Cardiotoxicity in hiPCS-CMs.
Adamcova M; Skarkova V; Seifertova J; Rudolf E
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31146354
[TBL] [Abstract][Full Text] [Related]
11. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Nemade H; Gaspar JA; Hescheler J; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Dec; 90(12):3087-3098. PubMed ID: 26842497
[TBL] [Abstract][Full Text] [Related]
13. Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2.
McLaughlin D; Zhao Y; O'Neill KM; Edgar KS; Dunne PD; Kearney AM; Grieve DJ; McDermott BJ
Br J Pharmacol; 2017 Nov; 174(21):3677-3695. PubMed ID: 28261787
[TBL] [Abstract][Full Text] [Related]
14. Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology.
Hayakawa T; Kunihiro T; Ando T; Kobayashi S; Matsui E; Yada H; Kanda Y; Kurokawa J; Furukawa T
J Mol Cell Cardiol; 2014 Dec; 77():178-91. PubMed ID: 25257913
[TBL] [Abstract][Full Text] [Related]
15. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
[TBL] [Abstract][Full Text] [Related]
16. Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Ellis JK; Wagh V; Nemade H; Hescheler J; Keun HC; Sachinidis A
Amino Acids; 2017 Dec; 49(12):1955-1963. PubMed ID: 28421296
[TBL] [Abstract][Full Text] [Related]
17. Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes.
Grafton F; Ho J; Ranjbarvaziri S; Farshidfar F; Budan A; Steltzer S; Maddah M; Loewke KE; Green K; Patel S; Hoey T; Mandegar MA
Elife; 2021 Aug; 10():. PubMed ID: 34338636
[TBL] [Abstract][Full Text] [Related]
18. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
[TBL] [Abstract][Full Text] [Related]
20. Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Nemade H; Sureshkumar P; Vinken M; Ates G; Rogiers V; Hescheler J; Hengstler JG; Sachinidis A
Arch Toxicol; 2018 Jan; 92(1):371-381. PubMed ID: 28940058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]